Apricus Biosciences Incorporated (NASDAQ:APRI) Stock Is Shorted Less

October 13, 2017 - By Adrian Erickson

 Apricus Biosciences Incorporated (NASDAQ:APRI) Stock Is Shorted Less

The stock of Apricus Biosciences Incorporated (NASDAQ:APRI) registered a decrease of 6.64% in short interest. APRI’s total short interest was 1.54M shares in October as published by FINRA. Its down 6.64% from 1.64M shares, reported previously. With 493,500 shares average volume, it will take short sellers 3 days to cover their APRI’s short positions. The short interest to Apricus Biosciences Incorporated’s float is 27.01%.

The stock decreased 2.09% or $0.04 on October 13, reaching $1.87. About 155,664 shares traded. Apricus Biosciences Inc (NASDAQ:APRI) has declined 71.78% since October 13, 2016 and is downtrending. It has underperformed by 88.48% the S&P500.

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The company has market cap of $23.91 million. The Firm primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. It currently has negative earnings. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Apricus Biosciences Inc (NASDAQ:APRI) Ratings Coverage

Among 6 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Apricus Bioscience Inc had 9 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Tuesday, September 5 by H.C. Wainwright. Ascendiant Capital Markets initiated the shares of APRI in report on Thursday, August 13 with “Buy” rating. The stock of Apricus Biosciences Inc (NASDAQ:APRI) earned “Outperform” rating by FBR Capital on Friday, November 6. TH Capital downgraded the shares of APRI in report on Friday, November 6 to “Neutral” rating. H.C. Wainwright maintained Apricus Biosciences Inc (NASDAQ:APRI) on Thursday, August 3 with “Buy” rating. Roth Capital downgraded Apricus Biosciences Inc (NASDAQ:APRI) rating on Friday, November 6. Roth Capital has “Neutral” rating and $1.50 target. As per Wednesday, August 30, the company rating was maintained by H.C. Wainwright. As per Wednesday, December 9, the company rating was downgraded by Sterne Agee CRT.

More notable recent Apricus Biosciences Inc (NASDAQ:APRI) news were published by: Globenewswire.com which released: “Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year …” on March 13, 2017, also Globenewswire.com with their article: “Apricus Biosciences Provides Corporate Update and Second Quarter 2017 …” published on August 02, 2017, Globenewswire.com published: “Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial …” on May 11, 2017. More interesting news about Apricus Biosciences Inc (NASDAQ:APRI) were released by: Seekingalpha.com and their article: “PDUFA Run-Up Idea: Apricus Biosciences” published on September 04, 2017 as well as Seekingalpha.com‘s news article titled: “Apricus Biosciences’ (APRI) CEO Richard Pascoe on Q1 2017 Results – Earnings …” with publication date: May 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.